[Long-term follow-up results after heavy dose chemotherapy of primary malignant bone tumors of the limbs].
Ninety-three cases of primary malignant bone tumors of the limbs were treated for 651 times with preoperative and postoperative HD-MTX-CFR regimen. A number of toxic side reactions appeared, most of which were those of the digestive tract. The side reactions treated symptomatically subsided uneventfully All cases were followed up for 5-7 years, 36 patients died and 57 survived with a 5-year survival rate of 61.3%. A new method to limb salvage was used in 44 cases: the bone segment with tumor was amputated, and replanted back after inactivation with alcohol excision. The five-year survival rate was 63.6%. The excellent results of treatment gave the patients new hope dispelling the misgivings of becoming disabled.
Cui
T H
TH
Taicang Rehabilitation Medical Center of Bone Tumors.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005266:Femoral Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality; D013977:Tibia
D004317:Doxorubicin; D002955:Leucovorin; D008727:Methotrexate